Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

BACKGROUND: We conducted a Phase I dose-escalation trial of ADMVA, a Clade-B'/C-based HIV-1 candidate vaccine expressing env, gag, pol, nef, and tat in a modified vaccinia Ankara viral vector. Sequences were derived from a prevalent circulating HIV-1 recombinant form in Yunnan, China, an area o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasan, Sandhya, Schlesinger, Sarah J., Chen, Zhiwei, Hurley, Arlene, Lombardo, Angela, Than, Soe, Adesanya, Phumla, Bunce, Catherine, Boaz, Mark, Boyle, Rosanne, Sayeed, Eddy, Clark, Lorna, Dugin, Daniel, Boente-Carrera, Mar, Schmidt, Claudia, Fang, Qing, Lei, Huang, Yaoxing, Zaharatos, Gerasimos J., Gardiner, David F., Caskey, Marina, Seamons, Laura, Ho, Martin, Dally, Len, Smith, Carol, Cox, Josephine, Gill, Dilbinder, Gilmour, Jill, Keefer, Michael C., Fast, Patricia, Ho, David D.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810329/
https://www.ncbi.nlm.nih.gov/pubmed/20111599
http://dx.doi.org/10.1371/journal.pone.0008816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810329/
https://www.ncbi.nlm.nih.gov/pubmed/20111599
http://dx.doi.org/10.1371/journal.pone.0008816

Ejemplares similares